课题基金 / 基金详情

Development and characterization of engineered therapeutic antibodies against SARS-CoV-2

Development and characterization of engineered therapeutic antibodies against SARS-CoV-2
针对 SARS-CoV-2 的工程化治疗抗体的开发和表征
批准号:
10669612
负责人:
Gaya K. Amarasinghe
金额:
$63.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-08-01 至 2024-07-31

项目摘要

项目成果

Gaya K. Amarasinghe的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
Project Summary/Abstract This R01 entitled, “Development and characterization of engineered therapeutic antibodies against SARS-CoV- 2”, builds on our project infrastructure, expertise, and experience in characterizing viral-host factor interactions in negative strand RNA viruses. Since originating in China, SARS-CoV-2 has since rapidly spread and is now a global pandemic. Significant concerns are that humans are immunologically naïve, and there are no available therapies. In the US, the disease has already overwhelmed the healthcare system in some states and have a serious knock-on effect in exacerbating the standard of care for other diseases. At the time of writing, nearly 5 million cases and >160,000 deaths have been attributed to COVID-19. The virus replicates in the lungs and causes a severe respiratory disease, COVID-19, which is fatal in >2% of cases. Neutralizing antibodies (nAbs) generated by natural infection or vaccines is known to control many infections and early studies in the current COVID-19 pandemic, including studies to test convalescent plasma treatments, are promising. These studies highlight the potential significance of nAb-based therapy. While IgG format of nAbs have long been the most extensively used format, early studies, including our own suggest that additional multivalent formats of nAbs may be more effective. This provides an innovative method to develop nAbs while acquiring potential benefits from effective neutralization at lower doses and lower likelihood of the emergence of resistance mutants. SARS-CoV- 2 is a single stranded, non-segmented, enveloped RNA virus. Viral infection requires interaction of the spike glycoprotein receptor binding domain (RBD) to the host receptor ACE2. Here, we will build on newly developed and established approaches that have been optimized through our work other systems to generate antibodies targeting spike and spike RBD using phage display technology and characterize their physical properties. We will engineer antibodies with increased valency and test for potency in in vitro neutralization assays and in vivo efficacy in a mouse model. At the completion, we expect to provide innovative and unique multivalent nAb leads with unique characteristics that will rival the best in class IgG drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing the role of LDL related receptor 1 (Lrp1) as host entry factor for multiple bunyaviruses
  • 批准号:
    10667857
  • 项目类别:
  • 资助金额:
    $78.36万
  • 财政年份:
    2023
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.
  • 批准号:
    10753347
  • 项目类别:
  • 资助金额:
    $24.77万
  • 财政年份:
    2023
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
  • 批准号:
    10683329
  • 项目类别:
  • 资助金额:
    $27.21万
  • 财政年份:
    2022
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
  • 批准号:
    10481430
  • 项目类别:
  • 资助金额:
    $29.65万
  • 财政年份:
    2022
  • 负责人:
    Gaya K. Amarasinghe
  • 依托单位:
国内基金
海外基金
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
  • 批准号:
    JCZRLH202600625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
  • 批准号:
    2026JJ50619
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    翁春艳
  • 依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
  • 批准号:
    82570085
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    沈慧
  • 依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
  • 批准号:
    82404910
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2024
  • 负责人:
    郝单丽
  • 依托单位: